# DESCRIPTION

## FIELD OF THE INVENTION

- introduce cancer biomarkers and diagnosis/treatment methods

## BACKGROUND OF THE INVENTION

- motivate need for early PDAC detection

## SUMMARY OF THE INVENTION

- introduce cancer cell biomarkers
- describe plectin-1 as a biomarker
- introduce methods of identifying accessible proteomes
- describe imaging compositions with magnetofluorescent nanoparticles
- introduce biomarkers for identifying cancer cells
- describe plectin-1 fragments as biomarkers
- introduce various types of cancer cells
- describe peptide ligands for binding to biomarkers
- introduce plectin-1 binding moieties
- describe detectable moieties and therapeutic agents
- introduce nanoparticle conjugates
- describe fluorochrome conjugates
- introduce bacteriophage displaying peptide ligands
- describe isolated bacteriophage displaying peptide ligands
- introduce diagnostic peptides
- describe labeled diagnostic peptides
- introduce methods for detecting cancer cells
- describe detecting subcellular localization of plectin-1
- introduce methods for detecting pancreatic ductal adenocarcinoma
- describe administering diagnostic compositions
- introduce methods for treating pancreatic ductal adenocarcinoma
- describe administering therapeutic compositions
- introduce methods for identifying pancreatic cancer cell peptide ligands
- describe phage-displayed peptide-receptor binding assays

## DEFINITIONS

- define article usage
- define patient or subject
- define animal
- define benefit
- define subject suspected of having cancer
- define subject at risk for cancer
- define suffering from disease
- define sample and specimen
- define biological samples
- define biopsy tissue
- define peptide, polypeptide, and protein
- define phage or bacteriophage
- define phage displayed peptide
- define phage display
- define isolated and purified
- define isolated phage
- define isolated peptide ligand
- define derives from
- define mimetic
- define small organic molecule
- define desired and fluorochrome derived from
- define nucleic acid molecule
- define gene
- define gene expression
- define label
- define linker
- define cell culture
- define epithelial cell
- define endothelial cells
- define ductal cell
- define pancreas
- define pancreatic cancer
- define adenocarcinoma
- define pancreatic ductal adenocarcinoma cell
- define characterizing cancer in subject
- define stem cell cancer markers
- define instructions for using the kit
- define other terms

## DETAILED DESCRIPTION OF THE INVENTION

- introduce cancer cell biomarkers and binding molecules for diagnosis and treatment
- describe accessible proteomes and methods of use for selecting biomarkers

### I. Methods for Identifying Pancreatic Cancer Cells

- motivate need for early pancreatic cancer diagnosis
- describe limitations of current detection methods
- introduce phage display screen and early passage PDAC cell lines
- describe use of peptide ligands for identifying PDAC cells
- discuss advantages of peptide targeting over antibody targeting
- describe development of multimodal nanoparticle-based targeted imaging agent
- discuss use of genetically engineered mouse models of PDAC
- describe screening for biomarkers and imaging agents using combinatorial chemistry
- summarize limitations of previous attempts at identifying PDAC biomarkers
- introduce plectin-1 as a novel biomarker for PDAC

### II. Peptide Ligands for Identifying “Accessible” Receptors in Proteomes of Pancreatic Cancer Cells

- describe use of phage display to identify peptides that distinguish PDAC cells
- introduce plectin-1 as a potential new biomarker for PDAC
- describe aberrant expression of plectin-1 in PDAC cells
- discuss potential roles of plectin-1 in signal transduction and disease progression
- summarize previous publications on plectin-1 overexpression in pancreatic cancer

### III. The “Accessible” Proteome as a Source of Cancer Cell Biomarkers

- describe phage display approach to screen for peptides that bind to PDAC cells
- introduce plectin-1 targeted peptides conjugated to magnetofluorescent nanoparticles
- describe detection of small PDAC and precursor lesions in engineered mouse models
- discuss characterization of biomarkers using affinity chromatography and sequencing
- summarize methods for determining sequence of identified binding molecules

### IV. Engineered Mouse Models of PDAC

- introduce genetically engineered mouse models of PDAC
- describe utility of mouse-human cancer models
- modify phage clone screening methods for peptide ligands

### V. Nanoparticle Based Imaging Labels and Diagnostic Methods for PDAC

- motivate noninvasive imaging for PDAC
- describe limitations of traditional imaging methods
- introduce peptide probes for biomarkers of incipient cancer cells
- contemplate translational studies for imaging molecules
- link peptide ligands to nanoparticle based imaging labels
- describe multimodal nanoparticle imaging probes
- administer contrast agents to subjects
- identify membrane-localized plectin-1 as a new biomarker for PDAC

### VI. Ligands as a Targeting Moiety to Deliver Therapeutic Payloads

- introduce ligand compositions as therapeutics
- advantages of ligand compositions
- use as targeting moiety for selective delivery of therapeutic payloads
- examples of therapeutic payloads
- attach peptide ligand to toxin
- attach peptide ligand to drug
- attach peptide ligand to enzymatically active toxins
- attach peptide ligand to radioisotope
- use of peptide ligand with prodrug activator
- link peptide ligand to viral surface proteins
- link peptide ligand to therapeutic agent directly
- incorporate peptide ligands into pharmaceutical compositions
- formulate pharmaceutical compositions for administration
- administer pharmaceutical compositions
- determine dosage, toxicity, and therapeutic efficacy
- estimate therapeutically effective dose
- administer therapeutic compounds
- use peptide ligands to enhance cancer cell sensitivity to additional anti-cancer treatments

### VIII. Antibodies

- provide isolated antibodies with affinity for cancer biomarker
- produce antibodies using protein as antigen
- prepare monoclonal antibody-producing cells
- screen for hybridoma producing antibody

### VIII. Designing Mimetics

- contemplate mimetics of plectin-1 biomarker
- describe methods for creating nonpeptide compounds
- synthesize nonpeptide compounds that mimic peptide sequences
- motivate multimeric compounds that repeat relevant peptide sequences
- describe solid phase method for synthesizing peptides
- evaluate sequence homology using Monte Carlo analysis
- identify peptide sequence derivatives using amino acid pairing technique
- describe protecting groups for peptide synthesis
- contemplate peptide ligands with non-naturally occurring amino acid residues
- describe methods for modifying peptides, including PEGylation
- motivate peptidomimetics of peptide ligands
- describe methods for creating peptidomimetics, including retro and inverso sequences

### IX. Small Molecule Drugs

- provide small molecule drugs that bind to cancer biomarker

## EXAMPLES

- describe experimental methods and results

### Example I

- introduce cell culture
- describe mouse cohorts
- outline phage selection
- explain enzyme-linked immunosorbent assay (ELISA) and multidimensional analysis
- describe phage labeling
- outline phage detection by fluorescent microscopy and flow cytometry
- describe ex vivo biopsy specimens
- identify a binding partner for a phage-expressed peptide
- verify clone 27 (Panc 27) binding to plectin-1
- describe subcellular fractionation
- outline competition experiments
- describe peptide synthesis
- outline CLIO-Cy5.5 synthesis
- describe intravital laser scanning microscopy
- outline biodistribution
- describe magnetic resonance imaging (MRI)
- outline histology and immunohistochemistry
- describe plectin-1 targeted peptide (PTP) synthesis
- describe plectin-1 targeted nanoparticle (PTP-NP) synthesis

### Example II

- select PDAC-specific peptides
- validate peptides using ELISA and flow cytometry

### Example III

- determine specificity of peptides for human PDACs

### Example IV

- utilize peptides for identifying human PDACs

### Example V

- test tumor localization of PDAC targeted phage

### Example VI

- identify plectin-1 as binding partner for peptide 27
- characterize plectin-1 expression in PDAC cells

### Example VII

- develop plectin-1 targeted PDAC imaging agents
- test imaging agents in vivo

### Other Embodiments

- discuss variations and modifications of the invention

